Barclays
MLNT

Barclays’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Barclays’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-56
Closed -$4K – 7513
2017
Q4 		$4K Buy
+56
New +$4.14K ﹤0.01% 6717

Barclays's MLNT Position: Q1 2020 in Review

Barclays sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 13 shares.

Barclays first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $498K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

  • Barclays reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 13 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020.
  • Barclays first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
  • Barclays's Melinta Therapeutics, Inc. Common Stock position peaked at $498K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.